SynthesisCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Transcatheter Left Ventricular Restoration in Ischemic Heart Failure and Dilated Cardiomyopathy.
Synthesis in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease is the leading global cause of death and frequently progresses to ischemic heart failure (IHF) after myocardial infarction through adverse left ventricular (LV)remodeling. Surgical LV restoration improves ventricular geometry and function but is limited by invasiveness and inconsistent outcomes. Transcatheter Left Ventricular Restoration (TLVR) has emerged as a minimally invasive alternative,employing devices such as Revivent TC, AccuCinch, and Parachute to reduce LV volume, wall stress, and improve LV ejection fraction (LVEF). While several studies have reported promising results, no prior meta-analysis has synthesized the evidence across devices. This meta-analysis followed PRISMA 2020 guidelines. PubMed, Embase, Scopus, and Cochrane Library were searched through July 2025. Eligible studies included adult patients with IHF or dilated cardiomyopathy undergoing TLVR and reporting outcomes including LVEF, LV end-diastolic volume (LVEDV), New York Heart Association (NYHA) class, or Kansas City Cardiomyopathy Questionnaire (KCCQ). Single-arm interventional and observational cohort studies were included. Data extraction was performed by four reviewers, with bias assessed using ROBINS-I and the Newcastle-Ottawa Scale. Pooled mean differences (MD) were calculated using a random-effects model (Hartung-Knapp-Sidik-Jonkman). Seventeen studies were included, with baseline LVEF 22.8%-38% and LVEDV 75-235 mL. TLVR significantly reduced LVEDV (MD -25.94 mL; p < 0.00001), increased LVEF (+6.69%; p < 0.00001), and improved the NYHA class (MD -0.73; p = 0.02). KCCQ scores improved in some studies but were not significant overall. Revivent TC and AccuCinch showed consistent benefits, whereas Parachute outcomes were more variable. This meta-analysis of TLVR demonstrates consistent improvements in LV remodeling, function, and symptoms. Nonetheless, high heterogeneity, small cohorts, and limited follow-up highlight the need for large randomized trials to establish durability, survival benefit, and refine patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.